MCMaxime Cochin

Maxime Cochin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maxime Cochin has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Franck Touret

    Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), France

    11 shared publications
  • Xavier de Lamballerie

    Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), France

    11 shared publications
  • Grégory Moureau

    Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), France

    8 shared publications
  • Antoine Nougairède

    Unité des Virus Émergents, UVE: Aix Marseille Université, IRD 190, INSERM 1207, Marseille, France

    7 shared publications
  • Antoine Nougairède

    Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France

    7 shared publications
  • Jean-Sélim Driouich

    Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA)

    7 shared publications

Latest Publications

  • Réponse et préparation à l'émergence des maladies virales : Thérapeutiques antivirales contre la COVID-19 et développement vaccinal contre l'encéphalite à tiques

    by Maxime Cochin

    La pandémie de COVID-19 a mis en lumière les faiblesses du système de lutte contre les maladies virales émergentes et les progrès considérables qui peuvent être accomplis dans ce domaine.Dès les premiers mois qui ont suivi l’émergence du SARS-CoV-2, nous avons développé une plateforme de recherche préclinique pour évaluer l’activité antivirale de molécules repositionnées. L’approche développée faisait appel à des tests in vitro sur différentes lignées cellulaires, des tests ex vivo sur des épithéliums bronchiques humains reconstitués et des tests in vivo chez le hamster, intégrant des paramètres virologiques, cliniques, histologiques et pharmacocinétiques. Les données précliniques générées sur les différentes molécules testées ont permis d’apporter des éléments tangibles aux différentes instances pilotant des essais cliniques.Une préparation à long terme est essentielle pour une gestion efficace des phénomènes d'émergence virale. C’est dans ce cadre que la deuxième partie de ce travail porte sur le développement d’une nouvelle méthode pour l’administration de souches virales atténuées. En utilisant le virus de l’encéphalite à tiques et l’expérience acquise dans le laboratoire dans le domaine de la génétique inverse, nous avons démontré que l’administration directe de fragments d’ADN subgénomiques chez la souris permettait la génération in vivo des particules virales infectieuses. Enfin, nous avons apporté la preuve de concept que cette méthode peut être appliquée efficacement pour administrer des souches virales atténuées.

  • Open Access

    De novo generation of viruses in animals: from infection models to vaccine development

    by Maxime Cochin, Jean-Sélim Driouich, Léa Luciani, Antoine Nougairède

    Reverse genetics is a valuable research tool in the field of virology with numerous applications. Primarily employed to recover viral strains in vitro , these approaches have also been used to generate viral strains directly in animals. This review presents a historical and technical overview of publications describing the rescue of viruses from injection of nucleic acids directly into animals since the 1950s. The injection of purified or cloned viral genomes in vivo has enabled the generation of many pathogens in a wide range of animal models. Recent advances in the delivery process of nucleic acid into cells have also contributed to this field of virology research, which currently focuses on creating a new generation of vaccines called DNA-launched live attenuated vaccines (LAVs). This new approach simplifies the administration of existing or newly created LAV strains, while providing better control of the inoculated material.

  • Open Access

    Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages

    by Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, Léa Luciani, Cécile Baronti, Ornéllie Bernadin, Magali Gilles, Paola Mariela Saba Villarroel, Grégory Moureau, Paul-Rémi Petit, et al.


  • Open Access

    In vivo rescue of arboviruses directly from subgenomic DNA fragments

    by Maxime Cochin, Jean-Sélim Driouich, Grégory Moureau, Géraldine Piorkowski, Xavier de Lamballerie, Antoine Nougairède

    Reverse genetic systems are mainly used to rescue recombinant viral strains in cell culture. These tools have also been used to generate, by inoculating infectious clones, viral strains directly in living animals. We previously developed the "Infectious Subgenomic Amplicons" (ISA) method, which enables the rescue of single-stranded positive sense RNA viruses in vitro by transfecting overlapping subgenomic DNA fragments. Here, we provide proof-of-concept for direct in vivo generation of infectious particles following the inoculation of subgenomic amplicons. First, we rescued a strain of tick-borne encephalitis virus in mice to transpose the ISA method in vivo. Subgenomic DNA fragments were amplified using a 3-fragment reverse genetics system and inoculated intramuscularly. Almost all animals were infected when quantities of DNA inoculated were at least 20 µg. We then optimized our procedure in order to increase the animal infection rate. This was achieved by adding an electroporation step and/or using a simplified 2- fragment reverse genetics system. Under optimal conditions, a large majority of animals were infected with doses of 20 ng of DNA. Finally, we demonstrated the versatility of this method by applying it to Japanese encephalitis and Chikungunya viruses. This method provides an efficient strategy for in vivo rescue of arboviruses. Furthermore, in the context of the development of DNA-launched live attenuated vaccines, this new approach may facilitate the generation of attenuated strains in vivo. It also enables to deliver a substance free of any vector DNA, which seems to be an important criterion for the development of human vaccines.


  • Open Access

    Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns

    by Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, Maxime Cochin, Léa Luciani, Ornéllie Bernadin, Caroline Laprie, Géraldine Piorkowski, Laurent Fraisse, Peter Sjö, et al.


  • Open Access

    In vivo rescue of arboviruses directly from subgenomic DNA fragments

    by Maxime Cochin, Jean-Sélim Driouich, Grégory Moureau, Géraldine Piorkowski, Xavier de Lamballerie, Antoine Nougairède

    Reverse genetic systems are mainly used to study RNA viruses and rescue recombinant strains in cell culture. Here, we provide proof-of-concept for direct in vivo viral generation using the ‘Infectious Subgenomic Amplicons’ method. So far, this procedure allowed to rescue in vitro RNA viruses, by the transfection of several overlapping subgenomic DNA fragments encoding the entire virus genome. We adapted and optimized this technique to generate a pathogenic tick-borne encephalitis virus strain in mice. To define optimal protocol parameters, we injected intramuscularly different amounts of DNA fragments associated, or not, to electroporation. The injection of only 1µg of DNA fragments combined with electroporation resulted in an infection rate of 100%. Then, these parameters were applied to rescue another flavivirus and an alphavirus. This method provides a novel and efficient strategy for in vivo viral generation, which is typically achieved by injecting infectious clones. Furthermore, as part of the development of DNA- launched live attenuated vaccines, this approach, which also has the advantage of not injecting vector DNA, may simplify the generation of attenuated strains in vivo .

  • Open Access

    Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

    by Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, et al.

    In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.


  • Open Access

    Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

    by Jean-Sélim Driouich, Maxime Cochin, Franck Touret, Paul-Rémi Petit, Magali Gilles, Grégory Moureau, Karine Barthélémy, Caroline Laprie, Thanaporn Wattanakul, Palang Chotsiri, et al.


  • Open Access

    The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model

    by Maxime Cochin, Léa Luciani, Franck Touret, Jean-Sélim Driouich, Paul-Rémi Petit, Grégory Moureau, Cécile Baronti, Caroline Laprie, Laurence Thirion, Piet Maes, et al.

    Late 2020, SARS-CoV-2 Alpha variant emerged in United Kingdom and gradually replaced G614 strains initially involved in the global spread of the pandemic. In this study, we use a Syrian hamster model to compare a clinical strain of Alpha variant with an ancestral G614 strain. The Alpha variant succeed to infect animals and to induce a pathology that mimics COVID-19. However, both strains replicate to almost the same level and induced a comparable disease and immune response. A slight fitness advantage is noted for the G614 strain during competition and transmission experiments. These data do not corroborate the epidemiological situation observed during the first half of 2021 in humans nor reports that showed a more rapid replication of Alpha variant in human reconstituted bronchial epithelium. This study highlights the need to combine data from different laboratories using various animal models to decipher the biological properties of newly emerging SARS-CoV-2 variants.


  • Open Access

    A simple reverse genetics method to generate recombinant coronaviruses

    by Julien Mélade, Géraldine Piorkowski, Franck Touret, Toscane Fourié, Jean‐Sélim Driouich, Maxime Cochin, Hawa Sophia Bouzidi, Bruno Coutard, Antoine Nougairède, Xavier de Lamballerie

    Engineering recombinant viruses is a pre‐eminent tool for deciphering the biology of emerging viral pathogens such as the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). However, the large size of coronavirus genomes renders the current reverse genetics methods challenging. Here, we describe a simple method based on “infectious subgenomic amplicons” (ISA) technology to generate recombinant infectious coronaviruses with no need for reconstruction of the complete genomic cDNA and apply this method to SARS‐CoV‐2 and also to the feline enteric coronavirus. In both cases we rescue wild‐type viruses with biological characteristics similar to original strains. Specific mutations and fluorescent red reporter genes can be readily incorporated into the SARS‐CoV‐2 genome enabling the generation of a genomic variants and fluorescent reporter strains for in vivo experiments, serological diagnosis, and antiviral assays. The swiftness and simplicity of the ISA method has the potential to facilitate the advance of coronavirus reverse genetics studies, to explore the molecular biological properties of the SARS‐CoV‐2 variants, and to accelerate the development of effective therapeutic reagents.